Proton Sponge Nanocomposites for Synergistic Tumor Elimination via Autophagy Inhibition-Promoted Cell Apoptosis and Macrophage Repolarization-Enhanced Immune Response

ACS Appl Mater Interfaces. 2024 Apr 10;16(14):17285-17299. doi: 10.1021/acsami.4c01451. Epub 2024 Mar 27.

Abstract

Cytoprotective autophagy and an immunosuppressive tumor microenvironment (TME) are two positive promoters for tumor proliferation and metastasis that severely hinder therapeutic efficacy. Inhibiting autophagy and reconstructing TME toward macrophage activation simultaneously are of great promise for effective tumor elimination, yet are still a huge challenge. Herein, a kind of dendrimer-based proton sponge nanocomposites was designed and constructed for tumor chemo/chemodynamic/immunotherapy through autophagy inhibition-promoted cell apoptosis and macrophage repolarization-enhanced immune response. These obtained nanocomposites contain a proton sponge G5AcP dendrimer, a Fenton-like agent Cu(II), and chemical drug doxorubicin (DOX). When accumulated in tumor regions, G5AcP can act as an immunomodulator to realize deacidification-promoted macrophage repolarization toward antitumoral type, which then secretes inflammatory cytokines to activate T cells. They also regulate intracellular lysosomal pH to inhibit cytoprotective autophagy. The released Cu(II) and DOX can induce aggravated damage through a Fenton-like reaction and chemotherapeutic effect in this autophagy-inhibition condition. Tumor-associated antigens are released from these dying tumor cells to promote the maturity of dendritic cells, further activating T cells. Effective tumor elimination can be achieved by this dendrimer-based therapeutic strategy, providing significant guidance for the design of a promising antitumor nanomedicine.

Keywords: autophagy inhibition; dendrimer; macrophage repolarization; proton sponge; synergistic tumor treatment.

MeSH terms

  • Apoptosis
  • Autophagy
  • Cell Line, Tumor
  • Dendrimers* / pharmacology
  • Doxorubicin / pharmacology
  • Doxorubicin / therapeutic use
  • Humans
  • Immunity
  • Macrophages
  • Nanocomposites* / therapeutic use
  • Neoplasms* / drug therapy
  • Protons
  • Tumor Microenvironment

Substances

  • Protons
  • Dendrimers
  • Doxorubicin